EICHORCondition: Cognition Disorders in Old Age · Cognitive and Behavioral Impairment · Sponsor: German University in Cairo
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Age \>60 years * Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment) Exclusion Criteria: * Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis) * Patients with history of L-arginine intolerance or allergy * Patients with asthma * Patients who recently had an acute myocardial infarction * Patients with history of stroke within 1 yaear * Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period. * Patients who initiated or stopped antihypertensive medications during the study period. * Patients who initiated or stopped antidiabetic medications during the study period. * Patients who initiated or stopped antihyperlipidemic medications during the study period. * Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function * Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics * Refusal to provide written informed consent
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Neurology Department, Al-Azhar University Hospitals | Cairo, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07338682